Lilly’s $3B European Bet on Oral GLP-1 Revolution
Eli Lilly is making a massive $3 billion strategic investment in European pharmaceutical manufacturing. The new Dutch facility represents a major shift in how blockbuster drugs like GLP-1 agonists will be produced and distributed globally.